MCL1 and melanoma: Using both in vitro and in vivo studies, with human and mouse samples, as well as analyses of a public clinical survival data dataset, this study provides strong evidence for a novel use of the MCL1 inhibitor S64315 to enhance the efficacy of immunotherapies against melanoma.